Use of sulfanegen and its analogs for prevention and treatment for neurodegenerative disorders

A 3-mercaptopyruvate prodrug, sulfanegen, that reduces neuroinflammation and oxidative stress for therapeutic use in neurodegenerative diseases.
Technology No. 2020-331
IP Status: Provisional Patent Application Filed; Application #: 63/054,631


  • Alzheimer’s Disease
  • Parkinson's Disease
  • Huntington's Disease
  • Cognitive Impairment
  • Non-Alcoholic Fatty Liver Disease/Non-alcoholic steatohepatitis (NAFLD/NASH)
  • Tylenol (acetaminophen) toxicity

Technology Overview

Sulfanegen is a prodrug of 3-mercaptopyruvic acid. Sulfanegen was studied for potential therapeutic benefit in Alzheimer's mouse models. In mice, sulfanegen at both doses 50 and 100 mg/kg showed a marked improvement in Alzheimer’s pathology and cognitive behavior pattern as determined by the T-maze spontaneous alternation.

Phase of Development

TRL: 3-4
In vitro neuroprotection studies and in vivo studies with biochemical and T-maze cognitive assessment tests have been conducted for sulfanegen. The researchers are currently evaluating the brain tissues of these mice for detailed mechanistic understanding of sulfanegen's neuroprotective action.

Desired Partnerships

This technology is now available for:
  • License
  • Sponsored research
  • Co-development

Please contact our office to share your business’ needs and learn more.


Questions about this technology?